Always Friends ans Association - Diabetes: New treatments offer prospects for disease control
In the world, ans with data from 2013, diabetes already affects approximately 371 million people. Here in Brazil, we are the fourth country in the world in number of cases, almost 13.4 million Brazilians, according ans to data in the same year.
Offer new possibilities for treatments with greater convenience, efficiency and control of blood sugar levels: these have been the focus of several studies in recent decades, with the aim of making life simpler and easier for diabetics.
Ask any diabetic who uses insulin which is their greatest discomfort. Can be sure that in most cases the person will complain of stinging needle and measures the glucose unit. The idea to synthesize in the laboratory an insulin that works and is not injectable is not new. In 2006 came to be marketed in the world an inhaled insulin, but was withdrawn from the market in 2007 because it was not widely accepted, since no abolished all injections ans during the day. In the following years, ans new studies followed and now the prospects of launching an oral insulin are much closer.
Until now it was known that when attempting to synthesize insulin placing it in compressed format, the digestive enzymes in our stomach and intestines were in charge of destroying it, making the treatment ineffective. Now, we developed a new type of tablet, in the initial tests, has demonstrated efficacy and safety profile suitable. This oral insulin is still in the testing stage, but emerges as a good promise ans for the coming years.
Why have a potential to differentiate into any other cell in the body, stem cells have been used in the treatment of diabetic patients, showing promising results. For decades, researchers try to transform stem cells into pancreatic cells, so they can produce insulin to the patient and provide their normal supply of this hormone. The attempt in the polls is precisely injecting these stem cells will produce insulin, without the patient having rejection.
One line of research is the use of stem cells from the patient to control their own immune system. It is known that Type 1 diabetes ans occurs when the body of the patient shall not recognize cells that produce insulin (pancreatic beta cells) and the attack by destroying them. In Brazil, a team of scientists from the University of São Paulo in Ribeirão Preto, has conducted several ans field studies, with encouraging results.
One of the leaders of this research, Dr. Eduardo Couri, has released the results of this work, including the "Autologous Transplantation of Hematopoietic Stem Cells in Type 1 Diabetic Patients newly diagnosed." The idea in this technique is the collection of stem cells for people with diabetes, ans followed by the use of drugs that force the immune system to shut down - like a chemotherapy - and in the sequel, injecting his own stem cells back into the patient a reorganization of the defense system, ans which does not attack the insulin-producing cells, thus preserving ans the pancreas occurs.
Another line of studies that have very advanced in recent ans years is the search with the nuclear transfer of somatic cells. ans These works, with recent publications in the second half of April 2013 by Dr Young Gie Chung group, in collaboration with the University of Seoul and the University of Los Angeles, has been successful in this technique.
Nuclear transfer is a stem cell receiving the nucleus of a cell and already differentiated mature, and thus may produce cells with various therapeutic purposes, similar to that which donated the core. With the development of this process will produce securely in laboratories pancreatic beta cells, insulin-producing cells, and thus regenerate the damaged pancreas, either type 1 or type 2 diabetes.
Was recently launched on the market ans a new class of drugs, inhibitors ans SLGT2. In some situations, our kidney reabsorbs glucose that has been filtered and you would go to the urine through a channel co-transporter, which is called SGLT2, the abbreviation for sodium-glucose cotransporters. The aim of these new drugs block is exactly the operation of the channel and increase the output ans of excess glucose in the urine, making the blood glucose drop and thus normalized. Several drugs have been developed in recent years: dapagliflozin, canagliflozina and empagliflozina. In Brazil, dapagliflozin is already available, and the canagliflozina is expected to arrive ans in the coming months.
Already on the market for several years, insulin pumps is presented each year more innovations are hardware,
In the world, ans with data from 2013, diabetes already affects approximately 371 million people. Here in Brazil, we are the fourth country in the world in number of cases, almost 13.4 million Brazilians, according ans to data in the same year.
Offer new possibilities for treatments with greater convenience, efficiency and control of blood sugar levels: these have been the focus of several studies in recent decades, with the aim of making life simpler and easier for diabetics.
Ask any diabetic who uses insulin which is their greatest discomfort. Can be sure that in most cases the person will complain of stinging needle and measures the glucose unit. The idea to synthesize in the laboratory an insulin that works and is not injectable is not new. In 2006 came to be marketed in the world an inhaled insulin, but was withdrawn from the market in 2007 because it was not widely accepted, since no abolished all injections ans during the day. In the following years, ans new studies followed and now the prospects of launching an oral insulin are much closer.
Until now it was known that when attempting to synthesize insulin placing it in compressed format, the digestive enzymes in our stomach and intestines were in charge of destroying it, making the treatment ineffective. Now, we developed a new type of tablet, in the initial tests, has demonstrated efficacy and safety profile suitable. This oral insulin is still in the testing stage, but emerges as a good promise ans for the coming years.
Why have a potential to differentiate into any other cell in the body, stem cells have been used in the treatment of diabetic patients, showing promising results. For decades, researchers try to transform stem cells into pancreatic cells, so they can produce insulin to the patient and provide their normal supply of this hormone. The attempt in the polls is precisely injecting these stem cells will produce insulin, without the patient having rejection.
One line of research is the use of stem cells from the patient to control their own immune system. It is known that Type 1 diabetes ans occurs when the body of the patient shall not recognize cells that produce insulin (pancreatic beta cells) and the attack by destroying them. In Brazil, a team of scientists from the University of São Paulo in Ribeirão Preto, has conducted several ans field studies, with encouraging results.
One of the leaders of this research, Dr. Eduardo Couri, has released the results of this work, including the "Autologous Transplantation of Hematopoietic Stem Cells in Type 1 Diabetic Patients newly diagnosed." The idea in this technique is the collection of stem cells for people with diabetes, ans followed by the use of drugs that force the immune system to shut down - like a chemotherapy - and in the sequel, injecting his own stem cells back into the patient a reorganization of the defense system, ans which does not attack the insulin-producing cells, thus preserving ans the pancreas occurs.
Another line of studies that have very advanced in recent ans years is the search with the nuclear transfer of somatic cells. ans These works, with recent publications in the second half of April 2013 by Dr Young Gie Chung group, in collaboration with the University of Seoul and the University of Los Angeles, has been successful in this technique.
Nuclear transfer is a stem cell receiving the nucleus of a cell and already differentiated mature, and thus may produce cells with various therapeutic purposes, similar to that which donated the core. With the development of this process will produce securely in laboratories pancreatic beta cells, insulin-producing cells, and thus regenerate the damaged pancreas, either type 1 or type 2 diabetes.
Was recently launched on the market ans a new class of drugs, inhibitors ans SLGT2. In some situations, our kidney reabsorbs glucose that has been filtered and you would go to the urine through a channel co-transporter, which is called SGLT2, the abbreviation for sodium-glucose cotransporters. The aim of these new drugs block is exactly the operation of the channel and increase the output ans of excess glucose in the urine, making the blood glucose drop and thus normalized. Several drugs have been developed in recent years: dapagliflozin, canagliflozina and empagliflozina. In Brazil, dapagliflozin is already available, and the canagliflozina is expected to arrive ans in the coming months.
Already on the market for several years, insulin pumps is presented each year more innovations are hardware,
No comments:
Post a Comment